Globus Medical price target raised to $106 from $91 at BofA

BofA analyst Travis Steed raised the firm’s price target on Globus Medical (GMED) to $106 from $91 and keeps a Buy rating on the shares. The Street is modeling only 70 basis points of operating margin expansion in 2026, but the firm thinks Nevro alone could help total company operating margins by 110 basis points, the analyst tells investors.